Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: Physician knowledge, patient adherence

被引:7
|
作者
Solem, Caitlyn [1 ]
Mody, Reema [2 ]
Stephens, Jennifer [1 ]
Macahilig, Cynthia [3 ]
Gao, Xin [1 ]
机构
[1] Pharmerit North Amer, Bethesda, MD 20814 USA
[2] Takeda Pharmaceut Int, Deerfield, IL USA
[3] Market Certitude Med Data Analyt, Parsippany, NJ USA
关键词
Gastroesophageal reflux disease; proton-pump inhibitors; survey; adherence; physicians; patients;
D O I
10.1331/JAPhA.2014.13117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To describe physicians' knowledge, patients' adherence, and perceptions of both regarding mealtime-related dosing directions for proton-pump inhibitors (PPIs). Design: Chart review and survey of patients and physicians. Setting: United States, with data collected between January and July 2011. Participants: Patients being treated for gastroesophageal reflux disease (GERD) with PPIs and their prescribing physicians. Main outcome measures: Patient-and physician-reported perception of PPI mealtime-related directions as important/ inconvenient (seven-point Likert scale; 7 = very important/ very inconvenient); physician-reported knowledge of PPI mealtime-related dosing directions based on whether the agent is labeled to be taken 30-60 minutes before eating (DIR-esomeprazole magnesium [Nexium-AstraZeneca], lansoprazole, and omeprazole) or labeled to be taken regardless of meals (NoDIR-dexlansoprazole [Dexilant-Takeda], rabeprazole, and pantoprazole); and patient-reported PPI mealtime-related directions received and adherence to directions. Results: Physicians (n = 262) recruited 501 patients who had been prescribed PPIs (262 DIR/239 NoDIR; mean age 51 years, 37% men, 56% nonerosive GERD [29% undocumented]). Across PPIs, physicians frequently reported incorrect directions or "did not know directions" (29% for esomeprazole to 69% for pantoprazole). While 98% of patients reported receiving directions from their physicians and 55% from their pharmacists, only 65% of DIR patients and 18% of NoDIR received directions consistent with product labeling. Physicians perceived greater inconvenience than patients (4.4 vs. 1.6, P < 0.001) and greater importance (5.2 vs. 4.5, P < 0.001) of mealtime-related directions. Overall, 81% of patients reported taking their PPI as directed. Conclusion: While this patient cohort was adherent to directions given, physicians' directions were often inconsistent with product labeling. Understanding physician and patient knowledge gaps may be critical to ensuring patients receive appropriate directions, improving patient adherence to specific dosing instructions, attaining positive therapy outcomes, and identifying opportunities for pharmacist-led interventions.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 50 条
  • [1] Physician and Patient Knowledge of and Adherence to Dosing Directions for Proton Pump Inhibitors in the Treatment of GERD
    Solem, Caitlyn T.
    Mody, Reema
    Stephens, Jennifer M.
    Macahilig, Cynthia
    Yu, Shawn S.
    Gao, Xin
    GASTROENTEROLOGY, 2012, 142 (05) : S581 - S581
  • [2] Patient and Physician Perceptions on Dosing Directions for Proton Pump Inhibitor (PPI) in the Treatment of Gastroesophageal Reflux Disease (GERD)
    Solem, Caitlyn
    Mody, Reema
    Stephens, Jennifer
    Macahilig, Cynthia
    Carpiuc, Kim Tran
    Gao, Xin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S411 - S411
  • [3] Efficacy of Proton-Pump Inhibitors in Children With Gastroesophageal Reflux Disease: A Systematic Review
    van der Pol, Rachel J.
    Smits, Marije J.
    van Wijk, Michiel P.
    Omari, Taher I.
    Tabbers, Merit M.
    Benninga, Marc A.
    PEDIATRICS, 2011, 127 (05) : 925 - 935
  • [4] Novel medical therapies for gastroesophageal reflux disease beyond proton-pump inhibitors
    Richter, JE
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2002, 31 (04) : S111 - +
  • [5] Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors
    Valentin Becker
    Stefan Grotz
    Christoph Schlag
    Simon Nennstiel
    Analena Beitz
    Bernhard Haller
    Roland M Schmid
    Alexander Meining
    Monther Bajbouj
    World Journal of Gastroenterology, 2014, (14) : 4017 - 4024
  • [6] Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review
    Miyazaki, Hirota
    Igarashi, Ataru
    Takeuchi, Toshihisa
    Teng, Lida
    Uda, Akihito
    Deguchi, Hisato
    Higuchi, Kazuhide
    Tango, Toshiro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (08) : 1316 - 1328
  • [7] The proton-pump inhibitor test in identifying gastroesophageal reflux disease-related globus
    Sinn, Deng Hyun
    Rhee, Poong-Iyul
    Lee, Jun Haeng
    Son, Hee Jung
    Chang, Dong Kyung
    Kim, Young-Ho
    Kim, Jae J.
    Rhee, Jong Chul
    GASTROENTEROLOGY, 2007, 132 (04) : A287 - A287
  • [8] Cost-effective management of gastroesophageal reflux disease: Is there a role for switching proton-pump inhibitors?
    Inadomi, JM
    Dodd, SL
    GASTROENTEROLOGY, 2005, 128 (04) : A526 - A526
  • [9] Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD
    Baumeler, Luzia
    Papakonstantinou, Eleni
    Milenkovic, Branislava
    Lacoma, Alicia
    Louis, Renaud
    Aerts, Joachim G.
    Welte, Tobias
    Kostikas, Konstantinos
    Blasi, Francesco
    Boersma, Wim
    Torres, Antoni
    Rohde, Gernot G. U.
    Boeck, Lucas
    Rakic, Janko
    Scherr, Andreas
    Tamm, Michael
    Stolz, Daiana
    RESPIROLOGY, 2016, 21 (05) : 883 - 890
  • [10] Economic Impact of Proton-Pump Inhibitors in Patients With Refractory Gastroesophageal Reflux Disease: A Managed Care Perspective
    Fu, An-Chen
    Mody, Reema
    Gerson, Lauren B.
    Tan, Hiangkiat
    GASTROENTEROLOGY, 2013, 144 (05) : S205 - S205